Compare NBN & PHAT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NBN | PHAT |
|---|---|---|
| Founded | 1872 | 2018 |
| Country | United States | United States |
| Employees | 234 | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 933.4M | 894.0M |
| IPO Year | N/A | 2019 |
| Metric | NBN | PHAT |
|---|---|---|
| Price | $108.69 | $10.58 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 6 |
| Target Price | ★ $117.50 | $19.50 |
| AVG Volume (30 Days) | 94.0K | ★ 940.4K |
| Earning Date | 04-28-2026 | 04-30-2026 |
| Dividend Yield | ★ 0.04% | N/A |
| EPS Growth | N/A | ★ 42.72 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $175,110,000.00 |
| Revenue This Year | $13.77 | $92.15 |
| Revenue Next Year | $18.72 | $59.79 |
| P/E Ratio | $11.29 | ★ N/A |
| Revenue Growth | N/A | ★ 216.93 |
| 52 Week Low | $78.17 | $2.21 |
| 52 Week High | $126.26 | $18.31 |
| Indicator | NBN | PHAT |
|---|---|---|
| Relative Strength Index (RSI) | 46.08 | 43.50 |
| Support Level | $104.40 | $10.06 |
| Resistance Level | $112.94 | $12.62 |
| Average True Range (ATR) | 3.66 | 0.67 |
| MACD | 0.31 | 0.08 |
| Stochastic Oscillator | 42.78 | 35.00 |
Northeast Bank provides banking and financial services to individual and corporate customers in the United States. The firm conducts its loan-related activities through two primary channels: the Community Banking Division, and the Small Business Administration (SBA) National Division. Its loan portfolio comprises residential mortgage loans; multi-family and other commercial real estate loans; commercial and industrial loans, consumer loans, and small business administration loans. The firm also provides telephone banking, online banking, mobile banking, and remote deposit capture services. The revenue of the company is derived principally from interest and dividends from the bank.
Phathom Pharmaceuticals Inc operates as a clinical-stage biopharmaceutical company. The firm is focused on developing and commercializing novel treatments for gastrointestinal, or GI, diseases. Its product comprises vonoprazan, an oral small-molecule potassium competitive acid blocker medicine that blocks acid secretion in the stomach. Vonoprazan shows rapid, potent, and durable anti-secretory effects and has demonstrated clinical benefits in the treatment of gastroesophageal reflux disease, and in combination with antibiotics for the treatment of Helicobacter pylori infection.